ReviewInternational journal of nanomedicine2026
Hydrogels in Autoimmune Disease: A Comprehensive Review of Current Research and Clinical Potentials.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research Objective: Autoimmune diseases are chronic conditions in which the immune system abnormally attacks the body's own tissues. Their incidence is on the rise, and the pathogenesis remains incompletely understood. The clinical manifestations are complex and diverse. Despite active treatment, some patients still have poor therapeutic outcomes and rely on immunosuppressants for a long time. Although these drugs can control symptoms, they are associated with increased infection risks and serious side effects such as organ toxicity. Hydrogels are three-dimensional network structures with excellent water absorption properties, good biocompatibility, injectability, and physical and chemical properties. By loading adjuvants, drugs, cells, and other substances, they are applied in the establishment of disease models, drug delivery, bioimaging and biosensors, tissue engineering, and other fields, providing new strategies for studying disease pathogenesis, drug screening, local targeted delivery, and immune regulation. This article aims to systematically review the mechanism of action and research progress of hydrogels in the treatment of autoimmune diseases and assess their potential for clinical translation. Research Methods: Relevant literature on the medical applications of hydrogels published from January 1, 2004 to October 31, 2025 was retrieved, and the scope was narrowed down to studies on their application in autoimmune diseases for summary and analysis. Main Results: The main findings are as follows: (1) Through bibliometric analysis, it was found that research on hydrogels in the medical field is increasingly prominent, with studies in autoimmune diseases mainly focusing on drug delivery; (2) By constructing injectable bioadhesive hydrogels, the adhesion of hydrogels to joint tissues is enhanced, prolonging drug retention time and improving treatment efficiency; (3) Specific hydrogel designs can actively regulate immune cell functions - for example, inhibiting inflammation-related signaling pathways to reverse M1 polarization of macrophages and ferritin autophagy/ferroptosis in chondrocytes, maintaining the integrity of cartilage structure, and inducing mitochondrial dysfunction to promote apoptosis of FLS and macrophages and regulate the inflammatory microenvironment; (4) Hydrogel microneedle systems, as transdermal drug delivery platforms, have shown good compliance and efficacy in rheumatoid arthritis. Summary: Hydrogel technology, through localized, controllable, and intelligent drug delivery, is expected to break through the bottlenecks of traditional autoimmune disease treatment. Current research is gradually evolving from passive carriers to active participants in immune regulation as "intelligent platforms", and their potential to reshape the inflammatory microenvironment has been verified in animal models. However, issues such as material degradability, long-term biological safety, and consistency in large-scale production still need to be further addressed in preclinical and clinical studies. Future interdisciplinary collaboration and translational medical research are key to promoting the development of this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.